Activated Factor X - Protease-Activated Receptors Signaling Promotes Vascular Inflammation and Atherosclerosis

• Project/Area Number: 26860565
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular medicine
• Research Institution: The University of Tokushima
• Principal Investigator: HARA Tomoya 徳島大学, 病院, 医員 (00644577)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: マクロファージ / 凝固因子 / 血液凝固因子 / 動脈硬化 / 炎症 / 凝固

Outline of Final Research Achievements

FXa-PARs signaling participates in the development of vascular inflammation. Results of our study suggests that this signaling pathway serves as a potential therapeutic target for atherosclerosis.

Research Products

• [Journal Article] Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. (2015)
  • Author(s): Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Sata M.
  • Journal Title: Atherosclerosis. Volume: 印刷中 Issue: 2 Pages: 639-646
  • DOI: 10.1016/j.atherosclerosis.2015.03.023
  • Peer Reviewed / Open Access
• [Presentation] Critical Role in Bone Marrow Protease-Activated Receptor-2 in the Pathogenesis of Vascular Inflammation and Atherosclerosis in ApoE-Deficient Mice (2016)
  • Author(s): 原知也
  • Organizer: 第80回日本循環器学会学術集会
  • Place of Presentation: 国際展示場（宮城県仙台市）
  • Year and Date: 2016-03-20
  • Int'l Joint Research
• [Presentation] Hematopoietic Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in ApoE-Deficient Mice (2015)
  • Author(s): Hara T
  • Organizer: AHA Scientific Sessions 2015
  • Place of Presentation: Orland, USA
  • Year and Date: 2015-11-09
  • Int'l Joint Research
• [Presentation] Rivaroxaban, a Direct Factor Xa Inhibitor, Attenuates Neointima Formation after Mechanical Vascular Injury (2014)
  • Author(s): Tomoya Hara, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata.
  • Organizer: The AHA 2014 Annual Membership Meeting
  • Place of Presentation: McCormick Place, Chicago (U.S.A.)
  • Year and Date: 2014-11-17
• [Presentation] Rivaroxaban, a direct factor Xa inhibitor, attenuates neointima formation following vascular injury in the mouse through the inhibition of proliferative activation of vascular smooth muscle cells. (2014)
  • Author(s): Tomoya Hara, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata.
  • Organizer: ESC Congress 2014
  • Place of Presentation: Fira Barcelona Gran Via Conference Centre, Barcelona (Spain)
  • Year and Date: 2014-09-02
• [Presentation] Rivaroxaban, a direct factor Xa inhibitor, attenuates plaque progression and destabilization in ApoE-deficient mice by inhibiting macrophage activation. (2014)
  • Author(s): Tomoya Hara, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata.
  • Organizer: ESC Congress 2014
  • Place of Presentation: Fira Barcelona Gran Via Conference Centre, Barcelona (Spain)
  • Year and Date: 2014-09-01